Sound Pharmaceuticals Wins Additional Funding
Sound Pharmaceuticals has received a R&D contract award from the Office of Naval Research for approximately $1.6 million to optimize its lead drug candidate for hearing regeneration.
Sound Pharmaceuticals has developed a proprietary technology for regenerating auditory sensory cells within the inner ear of mammals involving p27Kip1, a cyclin dependent kinase inhibitor or CKI.
In 2005, the Office of Naval Research began funding this hearing regeneration project. This new funding brings the total level of funding on this specific p27 project to approximately $3 million.